RYTM News and Press, Rhythm Pharmaceuticals Inc. From 09/06/22

-- Setmelanotide now FDA-approved and EC-authorized for Bardet-Biedl syndrome (BBS) -- -- EC authorization for BBS makes Rhythm eligible to receive second $37.5M tranche under Revenue Interest Agreement with HealthCare Royalty -- -- Health Canada grants Priority Review sta...

Looking for stocks that are beating the market in 2022? Our roundtable has three healthcare names that are killing it right now: Shockwave Medical (NASDAQ: SWAV) , Axsome Therapeutics (NASDAQ: AXSM) , and Rhythm Pharmaceuticals (NASDAQ: RYTM) . Read more to find out ...

Rising interest rates, sky-high inflation, and geopolitical turmoil have all conspired against U.S. stock markets this year. Despite a bear market rally over the past seven weeks, every major U.S. stock exchange is still down big for the year. For instance, the S&P 500 is curren...

The shares of Rhythm Pharmaceuticals ( NASDAQ: RYTM ) jumped ~14% in the morning hours Monday after Goldman Sachs upgraded the commercial-stage biotech to Buy from Neutral and raised the price target to $28 from $6, citing the potential of its weight loss therapy setmelanoti...

BofA analyst Tazeen Ahmad upgraded Rhythm Pharmaceuticals ( RYTM ) to Neutral from Underperform with a price target of $20, up from $8. The company is seeing a strong early BBS launch performance, Ahmad tells investors following the company's Q2 report. However, Ahmad awaits f...

BOSTON, Aug. 03, 2022 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM), a commercial-stage biopharmaceutical company focused on transforming the lives of patients and their families living with hyperphagia and severe obesity caused by rare melanocortin-4 receptor (MC4R) pathw...

Shares of Rhythm Pharmaceuticals (NASDAQ: RYTM) are surging Tuesday afternoon. As of 2:48 p.m. ET, the small-cap biotech's stock was up by a healthy 14.4% on sky-high volume. What's sparking this double-digit move higher? Prior to Tuesday's opening bell, Rhythm Pharmaceuticals a...

Rhythm Pharmaceuticals, Inc. (RYTM) Q2 2022 Results Earnings Conference Call August 2, 2022, 08:00 AM ET Company Participants David Connolly - Investor Relations and Corporate Communications David Meeker - Chairman, President and Chief Executive Officer Jennifer ...

Rhythm Pharmaceuticals ( NASDAQ: RYTM ) is trading 21% higher after the company posted narrower-than-expected Q2 loss, helped by sales of its genetic disorder drug, Imcivree and license revenue. The company posted Q2 GAAP EPS of -$0.89, which beat estimate...

Gainers: Quoin Pharmaceuticals ( QNRX ) +45% . Context Therapeutics CNTX +13% . Rhythm Pharmaceuticals RYTM +13% . Harmony Biosciences HRMY +10% . Nautilus Biotechnology NAUT +9% . Losers: Ontrak OTRK -43% . Phathom Pharmaceutical...